Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug
In a significant milestone for indigenous medical technology, India’s homegrown stroke treatment device has successfully cleared clinical trials, paving the way for wider clinical adoption and improved access to advanced neurovascular care across the country. The breakthrough underscores India’s growing capability to design, develop, and
Andhra Pradesh MedTech Zone (AMTZ), India’s premier medical technology manufacturing ecosystem, has announced the establishment of a new satellite centre of the Indian Institute of Health Management Research (IIHMR). The collaboration aims to advance public health research, healthcare management training, and innovation-driven capacity building within
The delegation comprised senior leaders, heads & directors from leading South Gujarat corporates & peer industries, brought together by CII to experience best-in-class manufacturing practices, innovation-driven processes & globally benchmarked quality systems. · The delegates were then taken through a guided tour of the state-of-the-art manufacturing facility
Healthium Medtech, a global medtech company with a growing portfolio across surgical, post-surgical, advanced wound care, arthroscopy and infection prevention, announced that it has agreed to acquire a controlling stake in Paramount Surgimed Ltd., one of India’s largest manufacturers and exporters of surgical blades, scalpels
India is rapidly cementing its position as a global powerhouse in the medical devices industry, driven by robust policy support, rising manufacturing capabilities, and increasing global demand for high quality, affordable medtech solutions. With a combination of strong domestic reforms and strategic international partnerships, the
Event organized by Informa Markets in India to bring over 2,000 exhibitors & 50,000 industry participants from more than 120 countries under one roof. Organized by Informa Markets in India, the 18th edition of CPHI & PMEC India 2025, South Asia's largest and most influential pharmaceutical industry event, is scheduled
Granules India Limited today announced that its wholly owned subsidiary, Granules Life Sciences Private Limited (GLS), located in Hyderabad (FEI: 3030495702), has received U.S. Food and Drug Administration (FDA) approval for a product that was the subject of a Pre- Approval Inspection (PAI) conducted between
Investment to expand manufacturing and global medicine supply capacity — resonating with the Make in India agenda Eli Lilly and Company today announced plans to invest more than $1 Billion over the next several years into new contract manufacturing in India, expanding patients’ access to innovative
Second quarter revenue from operations grows 4% sequentially and 2% year-on-year to Rs. 911 Cr 1st half revenue from operations up 6% Syngene International Limited today announced financial results for the second quarter and half year of FY26. Quarterly Financial Highlights (All numbers are in Indian Rupees in Cr except margins) Q2 FY25 Q2 FY26 YoY Change (%) Revenue from Operations 891 911 2% Reported Revenue 908 926 2% Reported EBITDA 261 215 -18% Reported EBITDA margin (%) 28.8% 23.2% Reported PAT (before exceptional items) 106 67 -37% Reported PAT Margin (%) 11.7% 7.3% H1 FY26 Financial Highlights (All numbers are in Indian rupees in Crores except margins) H1 FY25 H1 FY26 YoY Change (%) Revenue from Operations 1,681 1,785 6% Reported Revenue 1,715 1,818 6% Reported EBITDA 449 439 -2% Reported EBITDA margin (%) 26.2% 24.1% Reported PAT (before exceptional items) 161* 154 -4% Reported PAT Margin (%) 9.4% 8.5% Excludes exceptional item of Rs. 21 crores (net of tax) in Q1 FY25 relating to final settlement from an insurance claim. Commenting on the results, Peter Bains, Managing Director and CEO, Syngene International Limited, said, “Our Q2 performance was driven by underlying revenue growth from research
